Novartis late-breaking data further support initiation of Entresto in hospital and as a first-choice systolic heart failure therapy in stabilized patients

[In The News]

EAST HANOVER, N.J., March 16, 2019 /PRNewswire/ -- Novartis announced today new results from a 4-week extension of the landmark PIONEER-HF trial, presented as a late-breaker at the American College of Cardiology's 68th Annual Scientific Session. Data from the 8-week double-blind...

View the full article